Experts explore innovative bridging therapies for multiple myeloma, enhancing patient outcomes before CAR T-cell treatment while addressing significant challenges.

Researchers explore talquetamab as a bridge therapy for multiple myeloma patients before CAR T-cell treatment, assessing safety and efficacy outcomes.